David Dalton operates in the regulatory "grey zone," using carefully worded forward-looking statements that maximize promotional impact for retail investors while preserving plausible deniability. By announcing partnerships through unlisted private entities (like 11Three LLC or bioRemedies MD) rather than direct SEC filings, $UNVC generates market buzz without committing its own balance sheet or making legally binding representations in audited financial reports.
However, that "grey zone" strategy has clear legal limits: Misleading Omissions Under Securities Law: Federal courts have repeatedly held that even if individual statements are technically aspirational, omitting material facts necessary to make the overall narrative not misleading—s uch as failing to disclose that the company holds 0 active FDA NDCs or that the SENDS™ technology patent application is assigned to a third party (Landrace Bioscience)--can establish actionable securities fraud under SEC Rule 10b-5.
Explicit Drug Status Claims: Presenting physical "Rx Only" 5% Lidocaine box mockups as lead commercial assets crosses from aspirational "puffery" into explicit representations of regulated pharmaceutical status.
PL
However, that "grey zone" strategy has clear legal limits: Misleading Omissions Under Securities Law: Federal courts have repeatedly held that even if individual statements are technically aspirational, omitting material facts necessary to make the overall narrative not misleading—s uch as failing to disclose that the company holds 0 active FDA NDCs or that the SENDS™ technology patent application is assigned to a third party (Landrace Bioscience)--can establish actionable securities fraud under SEC Rule 10b-5.
Explicit Drug Status Claims: Presenting physical "Rx Only" 5% Lidocaine box mockups as lead commercial assets crosses from aspirational "puffery" into explicit representations of regulated pharmaceutical status.
PL
1
